乳腺癌新辅助内分泌治疗  

Neoadjuvant endocrine therapy in breast cancer

作　　者：张斌[1] 

机构地区：[1]辽宁省肿瘤医院乳腺科,辽宁省沈阳110042

出　　处：《中国癌症杂志》2006年第9期689-692,共4页China Oncology

摘　　要：新辅助化疗已是局部晚期乳腺癌的规范疗法,但对难以耐受化疗毒副反应的老年人局部晚期乳腺癌则是一治疗难题。文献资料显示,新辅助内分泌治疗是一有效方法,且患者易耐受。从新辅助内分泌治疗的总有效率和保乳手术率看,第三代芳香化酶抑制剂(第三代AI)效果明显优于他莫昔芬。新辅助内分泌治疗为绝经后ER(+)和/或PgR(+)的局部晚期或肿瘤较大的乳腺癌提供了一很好的治疗选择。Neoadjuvant chemotherapy is standard care of locally advanced primary breast cancer, but it is more difficult to treat elderly women with locally advanced breast cancer who cannot tolerate the toxicities of chemotherapy. According to the literature, neoadjuvant endocrine therapy seems to be effective and well tolerated. The clinical data （ overall response rates, conservative surgery rates） on 3rd generation aromatase inhibitors appears to be better than tamoxifen. Neoadjuvant endocrine therapy could be a reasonable alternative to chemotherapy for postmenopausal women with ER-positive and/or PgR-positive breast cancer.

关 键 词：乳腺癌 绝经后 ER 新辅助治疗 第三代芳香化酶抑制剂 他莫昔芬 

分 类 号：R737.9[医药卫生—肿瘤] R730.59[医药卫生—临床医学]